TOP10 reimbursement value in Poland – September 2024

?? Updated September 2024 #DGL bulletin data

?? In September 2024, the cumulative #reimbursement amount stands at PLN 17.5 billion, which is 4 billion more than in the same period of the previous year.

?? The ranking of the top three products across the entire market has remained stable. Meanwhile, #Perjeta made its debut in 10th position despite the fact that its refund value is 8.4% lower than a year earlier, and #Forxiga climbed to 4th place, achieving a cumulative reimbursement of PLN 245 million this year — a year-over-year growth of nearly 102%.

?? Within the chemotherapy category, #Vegzelma entered the rankings in 10th place with a cumulative reimbursement of PLN 9.8 million in 2024. #Besremi, on the other hand, surged to 3rd place, boasting a remarkable PLN 36.3 million reimbursement—a staggering 419% increase compared to last year.

?? On the outpatient list, #Trulicity advanced to 7th place with a PLN 100 million cumulative reimbursement this year. Meanwhile, #Ozempic held steady at 6th place, achieving a year-over-year growth in reimbursement of 130.6%.

?? Collectively, the year-over-year increase in reimbursement across all TOP10 brands in the entire market amounts to PLN 834 million, representing a substantial growth rate of 40.8%.

You can find more data in our IDA TOP10 report: https://app.powerbi.com/view?r=eyJrIjoiZGI3MDlkYWEtZDhmZi00MmIxLTlkNDctZTk3NjgyZWQyMjUyIiwidCI6IjFhYjJiNGUwLWE4ZmUtNGQ3OS1hY2Q1LTk2NzhlMThiN2IxOSIsImMiOjl9&embedImagePlaceholder=true